RadNet (NASDAQ:RDNT) Posts Earnings Results, Beats Expectations By $0.01 EPS

RadNet (NASDAQ:RDNT) issued its quarterly earnings data on Thursday. The medical research company reported $0.22 EPS for the quarter, topping the consensus estimate of $0.21 by $0.01, Zacks reports. RadNet had a negative net margin of 0.25% and a positive return on equity of 4.29%. The business had revenue of $477.10 million during the quarter, compared to analyst estimates of $459.42 million. RadNet updated its FY 2025 guidance to EPS.

RadNet Trading Down 5.6 %

Shares of RadNet stock traded down $3.25 during trading on Friday, hitting $54.35. The stock had a trading volume of 1,557,750 shares, compared to its average volume of 806,843. The company has a debt-to-equity ratio of 0.89, a current ratio of 2.16 and a quick ratio of 2.16. The firm’s fifty day simple moving average is $65.77 and its 200-day simple moving average is $69.04. RadNet has a 12 month low of $37.04 and a 12 month high of $93.65. The stock has a market cap of $4.02 billion, a PE ratio of -776.75 and a beta of 1.79.

Analyst Ratings Changes

Several brokerages have issued reports on RDNT. Truist Financial reissued a “buy” rating and issued a $88.00 target price (down from $94.00) on shares of RadNet in a research report on Wednesday, January 22nd. Jefferies Financial Group dropped their target price on shares of RadNet from $100.00 to $80.00 and set a “buy” rating for the company in a report on Wednesday, January 15th. Finally, Barclays dropped their price target on RadNet from $85.00 to $74.00 and set an “overweight” rating for the company in a research note on Wednesday, January 22nd. One investment analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, RadNet presently has an average rating of “Moderate Buy” and a consensus target price of $75.50.

About RadNet

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.